Collision tumor of the thyroid – a challenge during the COVID-19 pandemic
Abstract
Keywords
Full Text:
PDFReferences
Ragazzi M, Ciarrocchi A, Sancisi V, Bisagni A, Piana S. Update on anaplastic thyroid carcinoma: morphological, molecular, and genetic features of the most aggressive thyroid cancer. Int J Endocrinol. 2014; 790834. https://doi.org/10.1155/2014/790834
Are C, Shaha AR. Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol. 2006; 13(4):453-464. https://doi.org/10.1245/ASO.2006.05.042
Scosyrev E, Messing J, Noyes K, Veazie P, Messing E. Surveillance epidemiology and end results (SEER) program and population-based research in urologic oncology: an overview. Urol Oncol. 2012; 30(2):126-132. https://doi.org/10.1016/j.urolonc.2009.11.005
Yau T, Lo CY, Epstein RJ, Lam AKY, Wan KY, Lang BH. Treatment outcomes in anaplastic thyroid carcinoma: survival improvement in young patients with localized disease treated by combination of surgery and radiotherapy. Ann Surg Oncol. 2008; 15(9):2500-2505. https://doi.org/10.1245/s10434-008-0005-0
McIver B, Hay ID, Giuffrida DF, et al. Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery. 2001; 130(6):1028-1034. https://doi.org/10.1067/msy.2001.118266
Kebebew E, Greenspan FS, Clark OH, et al. Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer. 2005; 103(7):1330-1305. https://doi.org/10.1002/cncr.20936
Tan RK, Finley RK 3rd, Driscoll D, et al. Anaplastic carcinoma of the thyroid: a 24-year experience. Head Neck. 1995; 17(1):41-47. https://doi.org/10.1002/hed.2880170109
Nel CJ, van Heerden JA, Goellner JR, et al. Anaplastic carcinoma of the thyroid: a clinicopathologic study of 82 cases. Mayo Clin Proc. 1985; 60(1):51-58. https://doi.org/10.1016/s0025-6196(12)65285-9
Carcangiu ML, Steeper T, Zampi G, Rosai J. Anaplastic thyroid carcinoma. A study of 70 cases. Am J Clin Pathol. 1985; 83(2):135-158. https://doi.org/10.1093/ajcp/83.2.135
Ricarte-Filho JC, Ryder M, Chitale DA, et al. Mutational profile of advanced primary and metastatic radioactive iodine - refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res. 2009; 69(11):4885-4893. https://doi.org/10.1158/0008-5472.CAN-09-0727
Tessler FN, Middleton WD, Grant EG, et al. ACR thyroid imaging, reporting and data system (TI-RADS): white paper of the ACR TI-RADS Committee. J Am Coll Radiol. 2017; 14(5):587-595. https://doi.org/10.1016/j.jacr.2017.01.046
Patel KN, Shaha AR. Poorly differentiated and anaplastic thyroid cancer. Cancer Control. 2006; 13(2):119-128. https://doi.org/10.1177/107327480601300206
Us-Krasovec M, Golouh R, Auersperg M, Besic N, Ruparcic-Oblak L. Anaplastic thyroid carcinoma in fine needle aspirates. Acta Cytol. 1996; 40(5):953-958. https://doi.org/10.1159/000334007
Takano K, Kikuchi K, Matsumiya H, Himi T. Collision tumor of the thyroid: follicular carcinoma plus papillary carcinoma plus adenomatous goiter. World J Med Surg Case Rep. 2013; 2:21-25.
Molnar C, Molnar S, Bedekovics J, et al. Thryoid carcinoma coexisting with Hashimoto’s thyroiditis: clinicopathological and molecular characteristics clue up pathogenesis. Pathol Oncol Res. 2019; 25(3):1191-1197. https://doi.org/10.1007/s12253-019-00580-w
Junor EJ, Paul J, Reed NS. Anaplastic thyroid carcinoma: 91 patients treated by surgery and radiotherapy. Eur J Surg Oncol. 1992; 18(2):83-88.
Saunders CA, Nayar R. Anaplastic spindle-cell squamous carcinoma arising in association with tall-cell papillary cancer of the thyroid: a potential pitfall. Diagn Cytopathol. 1999; 21:413-418. https://doi.org/10.1002/(sici)1097-0339(199912)21:6<413::aid-dc10>3.0.co;2-n
Landa I, Ibrahimpasic T, Boucai L, et al. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest. 2016; 126:1052-1066. https://doi.org/10.1172/JCI85271
Rushton S, Burghel G, Wallace A, Nonaka D. Immunohistochemical detection of BRAF V600E mutation status in anaplastic thyroid carcinoma. Histopathology. 2016; 69:524-526. https://doi.org/10.1111/his.12964
Subbiah V, Kreitman RJ, Wainberg ZA, et al. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600E – mutant anaplastic thyroid cancer. J Clin Oncol. 2018; 36:7-13. https://doi.org/10.1200/JCO.2017.73.6785
Wang JR, Zafereo ME, Dadu R, et al. Complete surgical resection following neoadjuvant dabrafenib plus trametinib in BRAF V600E - mutated anaplastic thyroid carcinoma. Thyroid. 2019; 29(8):1036-1043. https://doi.org/10.1089/thy.2019.0133
Bible KC, Kebebew E, Brierley J, et al. 2021 American thyroid association guidelines for management of patients with anaplastic thyroid cancer. Thyroid. 2021; 31(3):337-386. https://doi.org/10.1089/thy.2020.0944
Anand A, Singh KR, Kushwaha JK, Hussain N, Sonkar AA. Papillary thyroid cancer and Hashimoto’s thyroiditis: an association less understood. Indian J Surg Oncol. 2014; 5(3):199-204. https://doi.org/10.1007/s13193-014-0325-4
Lun Y, Wu X, Xia Q, et al. Hashimoto’s thyroiditis as a risk factor of papillary thyroid cancer may improve cancer prognosis. Otolaryngol Head Neck Surg. 2013; 148(3):396-402. https://doi.org/10.1177/0194599812472426
DOI: http://dx.doi.org/10.22551/2021.33.0804.10189
Copyright (c) 2021 Mihaela Vlad, Ana Corlan, Melania Balas, Ioana Golu, Daniela Amzar, Emil Bistrian, Marioara Cornianu
Archive of Clinical Cases is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
ISSN: 2360-6975